Showing 1 - 10 of 92
"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. Generic utilization rates have risen substantially since the enactment of The Drug Price Competition and Patent Term Restoration Act...
Persistent link: https://www.econbiz.de/10003936940
Generic utilization rates have risen substantially since the enactment of The Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman) in 1984. In the year Hatch-Waxman was enacted, generic utilization rates were 19 percent; in contrast, today, the generic utilization rate is...
Persistent link: https://www.econbiz.de/10012462928
Persistent link: https://www.econbiz.de/10009298454
Persistent link: https://www.econbiz.de/10003516451
Persistent link: https://www.econbiz.de/10001175727
Persistent link: https://www.econbiz.de/10011817950
Payers often assess the benefits of new drugs relative to costs for reimbursement purposes, but they frequently exclude some drugs' option-related benefits, reducing their reimbursement chances, and making them less attractive R&D investments. We develop and test a real options model of R&D...
Persistent link: https://www.econbiz.de/10013004702
Patent litigation in the United States has increased dramatically in the last 20 years. Understanding this increase, and the concomitant increase in patent grants, can help us to better understand the sources of technological innovation and productivity. The approach described here provides a...
Persistent link: https://www.econbiz.de/10012716505
White seniors report better health than Black seniors in urban areas in Sao Paulo, Brazil. This is the case even after controlling for baseline health conditions and several demographic, socio-economic and family support characteristics. Furthermore, adjusted racial disparities in self-reported...
Persistent link: https://www.econbiz.de/10013223999
This paper models how the evolving field of pharmacogenomics (PG), which is the science of using genomic markers to predict drug response, may impact drug development times, attrition rates, costs, and the future returns to research and development (R&D). While there still remains an abundance...
Persistent link: https://www.econbiz.de/10013311658